SCHEMBL6491883

SCHEMBL6491883

O=S(=O)(c1ccccc1Cl)n1ncc2c(OC3CCNC3)cccc21

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 8/20 0.42
SLC6A2 P23975 6/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
HTR6 P50406 9/20 0.40
HTR7 P34969 2/20 0.40
HTR2B P41595 2/20 0.40
HTR1B P28222 1/20 0.39
TIPARP Q7Z3E1 1/20 0.39
HTR2C P28335 1/20 0.38
HSP90AB1 P08238 1/20 0.38
TOP2A P11388 1/20 0.38
MAP2K1 Q02750 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6493742 0.88 HTR1A (0.47) HTR1ASLC6A2SLC6A4SLC6A3HTR6
SCHEMBL6500353 0.88 HTR6 (0.51) HTR1AHTR6HTR7HTR2BHTR1B
SCHEMBL6495451 0.86 HTR6 (0.55) HTR1ASLC6A2HTR6TIPARP
SCHEMBL6495098 0.83 HTR6 (0.48) HTR1ASLC6A2HTR6HTR7HTR2B
SCHEMBL6502866 0.83 HTR6 (0.53) HTR1AHTR6HTR7HTR2BHTR1B
SCHEMBL6502181 0.83 HTR6 (0.44) HTR1ASLC6A2SLC6A4SLC6A3HTR6
SCHEMBL6495788 0.82 HTR6 (0.55) HTR1AHTR6HTR7HTR2BHTR1B
SCHEMBL6501474 0.78 ALDH1A1 (0.42) HTR6HSP90AB1TOP2A
SCHEMBL6496137 0.77 HTR6 (0.49) HTR1ASLC6A2HTR6HTR7HTR2B
SCHEMBL6493709 0.77 HTR6 (0.41) HTR6HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050065186-A1 Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-03-24 US claimed
EP-1385842-A1 HETEROCYCLYLOXY-, -THIOXY- AND -AMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS Wyeth (US) 2004-02-04 EP claimed
US-20030069278-A1 Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2003-04-10 US claimed
WO-2002085892-A1 HETEROCYCLYLOXY-, -THIOXY- AND -AMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2002-10-31 WO claimed
US-20050065186-A1 Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-03-24 US disclosed
US-6815456-B2 ANTISEROTONINE AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS WYETH 2004-11-09 US disclosed
EP-1385842-A1 HETEROCYCLYLOXY-, -THIOXY- AND -AMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS Wyeth (US) 2004-02-04 EP disclosed
US-20030069278-A1 Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2003-04-10 US disclosed
WO-2002085892-A1 HETEROCYCLYLOXY-, -THIOXY- AND -AMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2002-10-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065186-A1 Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR3B, HTR5A HTR1A 9/4885SLC6A2 117/4885SLC6A4 31/4885
US-20030069278-A1 Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR3B, HTR5A HTR1A 8/4885SLC6A2 133/4885SLC6A4 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.